secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2025-10-31T23:59:59+00:00
Accession:  0001683168-25-007871
Event type: other
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte stockholders authorize share issuance and approve 2.25M share increase to equity plan
--------------------------------------------------------------------------------

- Stockholders authorized issuance of shares underlying convertible preferred stock and warrants per August 2025 SPA (1,649,395 for, 249,100 against).
- Amendment to 2022 Equity Incentive Plan approved, increasing share reserve by 2,250,000 shares (2,348,827 for, 399,696 against).
- All three proposals passed at special meeting on Oct 30, 2025, with ~37.1% quorum (2,866,944 shares voted).
- Proposal 3 (adjournment) also passed: 2,496,898 for, 311,836 against, 58,210 abstentions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316825007871/0001683168-25-007871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316825007871/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-007871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer